prealbumin transthyretin
Selected indexed studies
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. (N Engl J Med, 2025) [PMID:39213194]
- Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. (J Am Coll Cardiol, 2019) [PMID:31171094]
- Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. (J Am Coll Cardiol, 2025) [PMID:40398971]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. (2025) pubmed
- Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. (2019) pubmed
- Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. (2025) pubmed
- Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. (2019) pubmed
- Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. (2024) pubmed
- A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). (2023) pubmed
- Cardiovascular Burden of the V142I Transthyretin Variant. (2024) pubmed
- Transthyretin variants impact blood-nerve barrier and neuroinflammation in amyloidotic neuropathy. (2025) pubmed
- Amyloid Cardiomyopathy. (2020) pubmed
- A Snapshot of the Most Recent Transthyretin Stabilizers. (2024) pubmed